Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
Conference: 20th Annual BIO CEO & Investor Conference
Date: February 12, 2018
Presentation Time: 3:30 PM EST
Date: February 13, 2018
The presentation materials for the BIO CEO & Investor conference will be posted at www.catalystpharma.com in the Investor section under Events and Presentations.
Catalyst is also developing CPP-115 to treat refractory infantile spasms. CPP-115 has been granted
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Brian Korb The Trout Group LLC(646) 378-2923 email@example.com Media Contact David Schull Russo Partners(212) 845-4271 firstname.lastname@example.org Company Contact Patrick J. McEnany Catalyst PharmaceuticalsChief Executive Officer (305) 420-3200 email@example.com
News Provided by Acquire Media